Pharma models changing as patents expire and product lines get smaller

Anyone watching stock markets recently will have noticed that despite overall gains, the pharmaceutical sector has not been performing. Not surprisingly, it is a combination of drugs coming off patent and a lack of a products in the pipeline that…

Get unlimited access to all IAM content